Silence Therapeutics PLC Sponsored ADR (NASDAQ:SLN) Receives Consensus Recommendation of “Hold” from Analysts

Silence Therapeutics PLC Sponsored ADR (NASDAQ:SLN) has been assigned an average rating of “Hold” from the six research firms that are presently covering the firm, Marketbeat.com reports. Two investment analysts have rated the stock with a sell recommendation and four have assigned a buy recommendation to the company. The average 12 month price target among analysts that have updated their coverage on the stock in the last year is $32.60.

A number of research firms have issued reports on SLN. Chardan Capital restated a “buy” rating and set a $35.00 target price on shares of Silence Therapeutics in a research report on Friday, August 8th. HC Wainwright restated a “buy” rating and issued a $75.00 price objective on shares of Silence Therapeutics in a report on Tuesday, September 16th. Wall Street Zen raised shares of Silence Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, November 8th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Silence Therapeutics in a research report on Wednesday, October 8th.

Hedge Funds Weigh In On Silence Therapeutics

Several institutional investors have recently modified their holdings of SLN. Cantor Fitzgerald L. P. increased its stake in shares of Silence Therapeutics by 1.6% in the 3rd quarter. Cantor Fitzgerald L. P. now owns 801,306 shares of the company’s stock valued at $4,159,000 after acquiring an additional 12,267 shares during the last quarter. UBS Group AG increased its stake in Silence Therapeutics by 34.5% in the third quarter. UBS Group AG now owns 307,363 shares of the company’s stock valued at $1,595,000 after purchasing an additional 78,854 shares in the last quarter. Millennium Management LLC raised its holdings in Silence Therapeutics by 50.3% in the third quarter. Millennium Management LLC now owns 298,512 shares of the company’s stock worth $1,549,000 after purchasing an additional 99,865 shares during the period. Boothbay Fund Management LLC boosted its position in shares of Silence Therapeutics by 10.8% during the third quarter. Boothbay Fund Management LLC now owns 279,637 shares of the company’s stock worth $1,451,000 after purchasing an additional 27,216 shares in the last quarter. Finally, Walleye Capital LLC grew its holdings in shares of Silence Therapeutics by 274.1% in the 1st quarter. Walleye Capital LLC now owns 136,150 shares of the company’s stock valued at $384,000 after buying an additional 99,753 shares during the period. 98.73% of the stock is currently owned by institutional investors and hedge funds.

Silence Therapeutics Trading Down 3.1%

SLN opened at $6.63 on Friday. Silence Therapeutics has a 1-year low of $1.97 and a 1-year high of $8.88. The stock has a market capitalization of $313.18 million, a PE ratio of -4.91 and a beta of 1.39. The firm has a 50-day moving average price of $6.25 and a two-hundred day moving average price of $5.74.

Silence Therapeutics (NASDAQ:SLN) last released its earnings results on Thursday, November 6th. The company reported ($0.45) EPS for the quarter, missing the consensus estimate of ($0.40) by ($0.05). The firm had revenue of $0.16 million during the quarter, compared to analyst estimates of $3.28 million. Silence Therapeutics had a negative net margin of 254.25% and a negative return on equity of 61.76%. On average, research analysts predict that Silence Therapeutics will post -1.77 EPS for the current year.

Silence Therapeutics Company Profile

Silence Therapeutics plc, a biotechnology company, focuses on the discovery and development novel molecules incorporating short interfering ribonucleic acid (siRNA) to inhibit the expression of specific target genes in hematology, cardiovascular, and rare diseases. The company's mRNAi GalNAc Oligonucleotide Discovery platform consists of precision engineered product candidates designed to target specific disease-associated genes in the liver.